Skip Navigation LinksHome > December 2013 - Volume 13 - Issue 6 > Reducing and managing systemic reactions to immunotherapy
Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e328364c876
IMMUNOTHERAPY AND NEW TREATMENTS: Edited by Giovanni Passalacqua and Robert Bush

Reducing and managing systemic reactions to immunotherapy

Ravi, Anupamaa; Rank, Matthew A.b

Collapse Box

Abstract

Purpose of review

To identify and discuss recent articles pertaining to the reduction and management of systemic reactions to allergen immunotherapy (AIT).

Recent findings

Fatal reactions to AIT may be declining. Screening asthma patients before AIT and dose adjustment during pollen season may contribute to lower systemic reaction rates. Cluster build-up protocols with multiallergen subcutaneous immunotherapy (SCIT) may lead to an increased risk of systemic reactions compared with cluster build-up protocols with single-allergen SCIT. Sublingual immunotherapy (SLIT) studies confirm the low rates of systemic reactions using this method, including for rapid build-up schedules. Studies of newer forms of AIT (intralymphatic, epicutaneous, recombinant allergens) have too few patients to form confident systemic reaction risk estimates. High-grade delayed systemic reactions to AIT may be less frequent than previously reported.

Summary

Recent studies increase confidence in risk estimates for systemic reactions to AIT, suggest useful strategies to predict systemic reactions to AIT, and offer strategies to prevent systemic reactions.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.